Sigma Planning Corp lowered its position in GlaxoSmithKline plc (NYSE:GSK) by 6.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 39,771 shares of the pharmaceutical company’s stock after selling 2,659 shares during the period. Sigma Planning Corp’s holdings in GlaxoSmithKline were worth $1,411,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of GSK. Hotchkis & Wiley Capital Management LLC boosted its holdings in GlaxoSmithKline by 7.3% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock worth $341,727,000 after buying an additional 569,600 shares during the period. Point72 Asset Management L.P. boosted its holdings in GlaxoSmithKline by 504.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 604,419 shares of the pharmaceutical company’s stock worth $24,539,000 after buying an additional 504,419 shares during the period. Seatown Holdings Pte. Ltd. bought a new position in GlaxoSmithKline in the 3rd quarter worth $20,148,000. Clark Estates Inc. NY lifted its stake in GlaxoSmithKline by 145.3% in the 4th quarter. Clark Estates Inc. NY now owns 650,000 shares of the pharmaceutical company’s stock worth $23,056,000 after purchasing an additional 385,000 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its stake in GlaxoSmithKline by 2.3% in the 3rd quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after purchasing an additional 293,866 shares in the last quarter. 9.52% of the stock is owned by institutional investors.

Shares of GlaxoSmithKline plc (GSK) opened at $36.22 on Tuesday. The company has a market cap of $88,660.00, a price-to-earnings ratio of 42.12, a price-to-earnings-growth ratio of 2.33 and a beta of 0.98. GlaxoSmithKline plc has a one year low of $34.52 and a one year high of $44.53. The company has a quick ratio of 0.39, a current ratio of 0.60 and a debt-to-equity ratio of 4.09.

GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.03. The firm had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. equities analysts forecast that GlaxoSmithKline plc will post 2.82 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be given a dividend of $0.633 per share. This represents a $2.53 annualized dividend and a dividend yield of 6.99%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio is currently 237.21%.

Several brokerages have commented on GSK. Kepler Capital Markets upgraded shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research note on Friday. TheStreet cut shares of GlaxoSmithKline from a “b-” rating to a “c” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, February 5th. ValuEngine cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $38.57.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline plc (GSK) Position Trimmed by Sigma Planning Corp” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-position-trimmed-by-sigma-planning-corp/1863399.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.